Cas No.: | 1357362-02-7 |
Chemical Name: | Vafidemstat |
Synonyms: | Vafidemstat;LZ82JLT4UP;Vafidemstat [INN];XBBRLCXCBCZIOI-DLBZAZTESA-N;BCP29383;5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine;5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine;1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-;ORY-2001;Vafidemstat (ORY-2001)?;SCHEMBL528204;CS-0058593;AKOS040742807;vafidemstatum;5-({[(1R,2S)-2-[4-(benzyloxy)phenyl]cyclopropyl]amino}methyl)-1,3,4-oxadiazol-2-amine;(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine;UNII-LZ82JLT4UP;1357362-02-7;MS-25100;1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-;HY-112623;5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine;BDBM50594947;DA-58938;ORY 2001; ORY-2001; ORY2001;G16394;CHEMBL4802155 |
SMILES: | O1C(N)=NN=C1CN[C@@H]1C[C@H]1C1C=CC(=CC=1)OCC1C=CC=CC=1 |
Formula: | C19H20N4O2 |
M.Wt: | 336.387703895569 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Vafidemstat is a dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor. |
Target: | LSD1/MAO-B[1] |
In Vitro: | Vafidemstat (ORY-2001), a dual LSD1/MAO-B inhibitor, is a novel epigenetic agent for the treatment of neurodegenerative diseases. LSD1 is a protein that participates in transcription regulation complexes; its modulation can be used to tweak transcriptional imbalances in neurodegenerative disease and redress neuroinflammation and cognitive deficit[1]. Vafidemstat (ORY-2001) can be used in the treatment of Alzheimer's disease[2]. |
References: | [1]. ORYZON presents data on the Phase I trial with ORY-2001 at the 13th International Conference on Alzheimer’s and Parkinson’s diseases [2]. ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2018. |